Profiling genomic copy number changes in retinoblastoma beyond loss of RB1
The DOI matches its Crossref record.
Abstract
Loss of both RB1 alleles is rate limiting for development of retinoblastoma (RB), but genomic copy number gain or loss may impact oncogene(s) and tumor suppressor genes, facilitating tumor progression. We used quantitative multiplex polymerase chain reaction to profile “hot spot” genomic copy number changes for gain at 1q32.1, 6p22, and MYCN, and loss at 16q22 in 87 primary RB and 7 cell lines. Loss at 16q22 (48%) negatively associated with MYCN gain (18%) (Fisher's exact P = 0.031), gain at 1q32.1 (62%) positively associated with 6p “hot spot” gain (43%) (P = 0.033), and there was a trend for positive association between 1q and MYCN gain (P = 0.095). Cell lines had a higher frequency of MYCN amplification than primary tumors (29% versus 3%; P= 0.043). Novel high‐level amplification of 1q32.1 in one primary tumor, confirmed by fluorescence in situ hybridization, strongly supports the presence of oncogene(s) in this region, possibly the mitotic kinesin, KIF14. Gene‐specific quantitative multiplex polymerase chain reaction of candidate oncogenes at 1q32.1 (KIF14), 6p22 (E2F3 and DEK), and tumor suppressor genes at 16q22 (CDH11) and 17q21 (NGFR) showed the most common gene gains in RB to be KIF14 in cell lines (80%) and E2F3 in primary tumors (70%). The patterns of gain/loss were qualitatively different in 25 RB compared with 12 primary hepatocellular carcinoma and 12 breast cancer cell lines. Gene specific analysis of one bone marrow metastasis of RB, prechemotherapy and postchemotherapy, showed the typical genomic changes of RB pretreatment, which normalized after chemotherapy. © 2006 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Dimaras, H., Kimani, K., Dimba, E. A., Gronsdahl, P., White, A., Chan, H. S., & Gallie, B. L. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61137-9 · Cited by 669
Self-citationDimaras, H., Corson, T. W., Cobrinik, D., White, A., Zhao, J., Munier, F. L., Abramson, D. H., Shields, C. L., Chantada, G. L., Njuguna, F., et al. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.21 · Cited by 553
Self-citationDimaras, H., Khetan, V., Halliday, W., Orlic, M., Prigoda, N. L., Piovesan, B., Marrano, P., Corson, T. W., Eagle, R. C., Squire, J. A., et al. (2008) · Human Molecular Genetics · doi:10.1093/hmg/ddn024 · Cited by 351
Self-citationOne hit, two hits, three hits, more? Genomic changes in the development of retinoblastoma
Corson, T. W., & Gallie, B. L. (2007) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.20457 · Cited by 278
Self-citationUnderstanding pRb: toward the necessary development of targeted treatments for retinoblastoma
Sachdeva, U. M., & O’Brien, J. M. (2012) · Journal of Clinical Investigation · doi:10.1172/jci57114 · Cited by 67
Metadata
- Authors
- Bowles, E., Corson, T. W., Bayani, J., Squire, J. A., Wong, N., Lai, P. B. ‐., & Gallie, B. L.
- Venue
- Genes, Chromosomes and Cancer
- Publisher
- Wiley
- Published
- 2006-11-10
- Volume
- 46
- Issue
- 2
- Pages
- 118-129
- ISSN
- 1045-2257 (ISSN-L)
- 1098-2264
- OpenAlex
- W2046598182
- Cited by
- 110
- References
- 0
- FWCI
- 5.75
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Profiling genomic copy number changes in retinoblastoma beyond loss of RB1. https://app.cochat.ai/papers/10.1002/gcc.20383
- The paper
- Bowles, E., Corson, T. W., Bayani, J., Squire, J. A., Wong, N., Lai, P. B. ‐., & Gallie, B. L. (2007). Profiling genomic copy number changes in retinoblastoma beyond loss of RB1. Genes, Chromosomes and Cancer. https://doi.org/10.1002/gcc.20383
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.